Physician profile
Christoph Lam
NPI 1750461976
$12,944.67
in general payments reported to CMS, 2019-2025
17 companies · $460 in 2025
The $460 reported for 2025 was more than what 75% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $298 · 2021: $804 · 2022: $213 · 2023: $331 · 2024: $46.83 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $10,000.00 | 2019 | |
| Supernus Pharmaceuticals, INC. | $1,136.68 | 2019-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $398.54 | 2020-2025 | Caplyta |
| Corium, LLC | $380.01 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $247.97 | 2019-2022 | |
| Bausch Health US, LLC | $146.03 | 2019-2025 | Aplenzin |
| Sunovion Pharmaceuticals INC. | $131.09 | 2020 | |
| Rhodes Pharmaceuticals L.P. | $113.32 | 2019 | |
| Tris Pharma INC | $109.05 | 2019-2023 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $71.50 | 2020-2021 | |
| Shire North American Group INC | $69.31 | 2019 | |
| Ironshore Pharmaceuticals INC. | $37.77 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $30.16 | 2023 | Quviviq |
| Neos Therapeutics, LP | $27.19 | 2019-2020 | |
| Abbvie INC. | $16.95 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Owp Pharmaceuticals, INC. | $14.82 | 2023 | Lamotrigine, Subvenite |
| Collegium Pharmaceutical, INC. | $14.28 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christoph Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.